Kesatuan Eropah -
Slovenia -
EMA (European Medicines Agency)
naxcel
zoetis belgium sa - ceftiofur - antibakterij za sistemsko uporabo - pigs; cattle - pigstreatment of bacterial respiratory disease associated with actinobacillus pleuropneumoniae, pasteurella multocida, haemophilus parasuis and streptococcus suis. zdravljenje septikemije, poliartritisa ali poliserozitisa, povezane z okužbo s streptococcus suis. cattletreatment of acute interdigital necrobacillosis in cattle also known as panaritium or foot rot. zdravljenje akutnega posttornega (puerperalnega) metritisa pri govedu, če zdravljenje z drugim protimikrobnim zdravilom ni uspelo.
Slovenia -
Slovenia -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
metricure
intervet international -
Kesatuan Eropah -
Slovenia -
EMA (European Medicines Agency)
yescarta
kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastična sredstva - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.
Slovenia -
Slovenia -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
cevaxel rtu
ceva santé animale -
Kesatuan Eropah -
Slovenia -
EMA (European Medicines Agency)
abecma
bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastična sredstva - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.